BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Marchioni RM, Lichtenstein GR. Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol 2013; 19(17): 2591-2602 [PMID: 23674866 DOI: 10.3748/wjg.v19.i17.2591] [Cited by in CrossRef: 70] [Cited by in F6Publishing: 55] [Article Influence: 10.0] [Reference Citation Analysis]
Number Citing Articles
1 Pendeloski KPT, Ono E, Torloni MR, Mattar R, Daher S. Maternal obesity and inflammatory mediators: A controversial association. Am J Reprod Immunol 2017;77. [PMID: 28328066 DOI: 10.1111/aji.12674] [Cited by in Crossref: 23] [Cited by in F6Publishing: 25] [Article Influence: 5.8] [Reference Citation Analysis]
2 Bortlik M, Duricova D, Machkova N, Kozeluhova J, Kohout P, Hrdlicka L, Durilova M, Mitrova K, Hradsky O, Bronsky J, Malickova K, Lukas M. Impact of Anti–Tumor Necrosis Factor Alpha Antibodies Administered to Pregnant Women With Inflammatory Bowel Disease on Long-term Outcome of Exposed Children: . Inflammatory Bowel Diseases 2014;20:495-501. [DOI: 10.1097/01.mib.0000440984.86659.4f] [Cited by in Crossref: 57] [Cited by in F6Publishing: 10] [Article Influence: 8.1] [Reference Citation Analysis]
3 Carman WJ, Accortt NA, Anthony MS, Iles J, Enger C. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. Pharmacoepidemiol Drug Saf 2017;26:1109-18. [PMID: 28758274 DOI: 10.1002/pds.4261] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
4 Porter C, Armstrong-Fisher S, Kopotsha T, Smith B, Baker T, Kevorkian L, Nesbitt A. Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): Consequences for FcRn-mediated in vitro transcytosis and ex vivo human placental transfer. J Reprod Immunol 2016;116:7-12. [PMID: 27123565 DOI: 10.1016/j.jri.2016.04.284] [Cited by in Crossref: 50] [Cited by in F6Publishing: 46] [Article Influence: 10.0] [Reference Citation Analysis]
5 Tsao NW, Lynd LD, Sadatsafavi M, Hanley G, De Vera MA. Patterns of Biologics Utilization and Discontinuation Before and During Pregnancy in Women With Autoimmune Diseases: A Population-Based Cohort Study. Arthritis Care Res 2018;70:979-86. [DOI: 10.1002/acr.23434] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
6 Vigl K, Posch C, Richter L, Monshi B, Rappersberger K. Pyoderma gangrenosum during pregnancy - treatment options revisited. J Eur Acad Dermatol Venereol 2016;30:1981-4. [DOI: 10.1111/jdv.13792] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
7 Papamichael K, Mantzaris GJ, Peyrin-Biroulet L. A safety assessment of anti-tumor necrosis factor alpha therapy for treatment of Crohn's disease. Expert Opin Drug Saf 2016;15:493-501. [PMID: 26799429 DOI: 10.1517/14740338.2016.1145653] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 5.0] [Reference Citation Analysis]
8 Hoxha A, Calligaro A, Di Poi E, Peccatori S, Favaro M, Del Ross T, Ramonda R, Grava C, Raffeiner B, Ravagni P, De Vita S, Ruffatti A. Pregnancy and foetal outcomes following anti-tumor necrosis factor alpha therapy: A prospective multicentre study. Joint Bone Spine 2017;84:169-73. [DOI: 10.1016/j.jbspin.2016.03.014] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 4.5] [Reference Citation Analysis]
9 Mekinian A, Cohen J, Kayem G, Carbillon L, Nicaise-roland P, Gaugler B, Darai E, Bornes M, Fain O. Fausses couches précoces récurrentes inexpliquées : quelle est la place de l’immunomodulation ? La Revue de Médecine Interne 2017;38:264-8. [DOI: 10.1016/j.revmed.2016.08.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Mahadevan U, Long MD, Kane SV, Roy A, Dubinsky MC, Sands BE, Cohen RD, Chambers CD, Sandborn WJ; Crohn’s Colitis Foundation Clinical Research Alliance. Pregnancy and Neonatal Outcomes After Fetal Exposure to Biologics and Thiopurines Among Women With Inflammatory Bowel Disease. Gastroenterology 2021;160:1131-9. [PMID: 33227283 DOI: 10.1053/j.gastro.2020.11.038] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 18.0] [Reference Citation Analysis]
11 Ngian GS, Briggs AM, Ackerman IN, Van Doornum S. Safety of anti-rheumatic drugs for rheumatoid arthritis in pregnancy and lactation. Int J Rheum Dis 2016;19:834-43. [PMID: 27125255 DOI: 10.1111/1756-185X.12860] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Vena GA, Cassano N, Bellia G, Colombo D. Psoriasis in pregnancy: challenges and solutions. Psoriasis (Auckl) 2015;5:83-95. [PMID: 29387585 DOI: 10.2147/PTT.S82975] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
13 Köhler BM, Günther J, Kaudewitz D, Lorenz HM. Current Therapeutic Options in the Treatment of Rheumatoid Arthritis. J Clin Med 2019;8:E938. [PMID: 31261785 DOI: 10.3390/jcm8070938] [Cited by in Crossref: 48] [Cited by in F6Publishing: 34] [Article Influence: 24.0] [Reference Citation Analysis]
14 Ghalandari N, Dolhain RJEM, Hazes JMW, van Puijenbroek EP, Kapur M, Crijns HJMJ. Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review. Drugs 2020;80:1699-722. [PMID: 32852745 DOI: 10.1007/s40265-020-01376-y] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mekinian A, Cohen J, Alijotas-reig J, Carbillon L, Nicaise-roland P, Kayem G, Daraï E, Fain O, Bornes M. Unexplained Recurrent Miscarriage and Recurrent Implantation Failure: Is There a Place for Immunomodulation? Am J Reprod Immunol 2016;76:8-28. [DOI: 10.1111/aji.12493] [Cited by in Crossref: 57] [Cited by in F6Publishing: 49] [Article Influence: 11.4] [Reference Citation Analysis]
16 Clowse ME, Wolf DC, Förger F, Cush JJ, Golembesky A, Shaughnessy L, De Cuyper D, Mahadevan U. Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol. J Rheumatol 2015;42:2270-8. [DOI: 10.3899/jrheum.140189] [Cited by in Crossref: 51] [Cited by in F6Publishing: 39] [Article Influence: 8.5] [Reference Citation Analysis]
17 Felis-Giemza A. New era of treatment with biologics in rheumatology - is it time to shift paradigms in treatment with biologics? Reumatologia 2019;57:255-6. [PMID: 31844337 DOI: 10.5114/reum.2019.89515] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Horst S, Kane S. The use of biologic agents in pregnancy and breastfeeding. Gastroenterol Clin North Am 2014;43:495-508. [PMID: 25110255 DOI: 10.1016/j.gtc.2014.05.005] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
19 Plavšić I, Stimac T, Hauser G. Crohn's disease in women. Int J Womens Health 2013;5:681-8. [PMID: 24204175 DOI: 10.2147/IJWH.S38083] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
20 Weber-Schoendorfer C, Oppermann M, Wacker E, Bernard N, Beghin D, Cuppers-Maarschalkerweerd B, Richardson JL, Rothuizen LE, Pistelli A, Malm H, Eleftheriou G, Kennedy D, Kadioglu Duman M, Meister R, Schaefer C; network of French pharmacovigilance centres. Pregnancy outcome after TNF-α inhibitor therapy during the first trimester: a prospective multicentre cohort study. Br J Clin Pharmacol 2015;80:727-39. [PMID: 25808588 DOI: 10.1111/bcp.12642] [Cited by in Crossref: 93] [Cited by in F6Publishing: 80] [Article Influence: 15.5] [Reference Citation Analysis]
21 Leung KK, Tandon P, Govardhanam V, Maxwell C, Huang V. The Risk of Adverse Neonatal Outcomes With Maternal Inflammatory Bowel Disease: A Systematic Review and Meta-analysis. Inflamm Bowel Dis 2021;27:550-62. [PMID: 32469057 DOI: 10.1093/ibd/izaa122] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
22 Saavedra Salinas MÁ, Barrera Cruz A, Cabral Castañeda AR, Jara Quezada LJ, Arce-salinas CA, Álvarez Nemegyei J, Fraga Mouret A, Orozco Alcalá J, Salazar Páramo M, Cruz Reyes CV, Andrade Ortega L, Vera Lastra OL, Mendoza Pinto C, Sánchez González A, Cruz Cruz PDR, Morales Hernández S, Portela Hernández M, Pérez Cristóbal M, Medina García G, Hernández Romero N, Velarde Ochoa MDC, Navarro Zarza JE, Portillo Díaz V, Vargas Guerrero A, Goycochea Robles MV, García Figueroa JL, Barreira Mercado E, Amigo Castañeda MC. Guías de práctica clínica para la atención del embarazo en mujeres con enfermedades reumáticas autoinmunes del Colegio Mexicano de Reumatología. Parte II. Reumatología Clínica 2015;11:305-15. [DOI: 10.1016/j.reuma.2014.12.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
23 Nguyen GC, Seow CH, Maxwell C, Huang V, Leung Y, Jones J, Leontiadis GI, Tse F, Mahadevan U, van der Woude CJ; IBD in Pregnancy Consensus Group; Canadian Association of Gastroenterology. The Toronto Consensus Statements for the Management of Inflammatory Bowel Disease in Pregnancy. Gastroenterology. 2016;150:734-757.e1. [PMID: 26688268 DOI: 10.1053/j.gastro.2015.12.003] [Cited by in Crossref: 224] [Cited by in F6Publishing: 183] [Article Influence: 37.3] [Reference Citation Analysis]
24 Kumar M, Ray L, Vemuri S, Simon TA. Pregnancy outcomes following exposure to abatacept during pregnancy. Seminars in Arthritis and Rheumatism 2015;45:351-6. [DOI: 10.1016/j.semarthrit.2015.06.016] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 5.7] [Reference Citation Analysis]
25 Fujita H, Terui T, Hayama K, Akiyama M, Ikeda S, Mabuchi T, Ozawa A, Kanekura T, Kurosawa M, Komine M, Nakajima K, Sano S, Nemoto O, Muto M, Imai Y, Yamanishi K, Aoyama Y, Iwatsuki K; The Japanese Dermatological Association Guidelines Development Committee for the Guidelines for the Management and Treatment of Generalized Pustular Psoriasis. Japanese guidelines for the management and treatment of generalized pustular psoriasis: The new pathogenesis and treatment of GPP. J Dermatol 2018;45:1235-70. [DOI: 10.1111/1346-8138.14523] [Cited by in Crossref: 38] [Cited by in F6Publishing: 27] [Article Influence: 12.7] [Reference Citation Analysis]
26 Huang VW, Habal FM. From conception to delivery: managing the pregnant inflammatory bowel disease patient. World J Gastroenterol 2014;20:3495-506. [PMID: 24707132 DOI: 10.3748/wjg.v20.i13.3495] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
27 Wispelwey BP, Sheiner E. Inflammatory bowel disease and preterm delivery. Arch Gynecol Obstet 2013;288:725-30. [DOI: 10.1007/s00404-013-2989-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Laube R, Paramsothy S, Leong RW. Use of medications during pregnancy and breastfeeding for Crohn's disease and ulcerative colitis. Expert Opin Drug Saf 2021;20:275-92. [PMID: 33412078 DOI: 10.1080/14740338.2021.1873948] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Chang J, Leong RW. Occupational health and safety of anti-tumour necrosis factor alpha monoclonal antibodies with casual exposure. Expert Opinion on Biological Therapy 2013;14:27-36. [DOI: 10.1517/14712598.2014.853738] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
30 Wieringa JW, Driessen GJ, Van Der Woude CJ. Pregnant women with inflammatory bowel disease: the effects of biologicals on pregnancy, outcome of infants, and the developing immune system. Expert Rev Gastroenterol Hepatol 2018;12:811-8. [PMID: 29972674 DOI: 10.1080/17474124.2018.1496820] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
31 George EM. New approaches for managing preeclampsia: clues from clinical and basic research. Clin Ther 2014;36:1873-81. [PMID: 25450475 DOI: 10.1016/j.clinthera.2014.09.023] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 2.1] [Reference Citation Analysis]
32 Wieringa JW, van der Woude CJ. Effect of biologicals and JAK inhibitors during pregnancy on health-related outcomes in children of women with inflammatory bowel disease. Best Pract Res Clin Gastroenterol 2020;44-45:101665. [PMID: 32359679 DOI: 10.1016/j.bpg.2019.101665] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
33 Acosta-Felquer ML, Rosa J, Soriano ER. An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy. Open Access Rheumatol 2016;8:37-44. [PMID: 27843368 DOI: 10.2147/OARRR.S56837] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
34 Belinchón I, Velasco M, Ara-Martín M, Armesto Alonso S, Baniandrés Rodríguez O, Ferrándiz Pulido L, García-Bustinduy M, Martínez-López JA, Martínez Sánchez N, Pérez Ferriols A, Pérez Pascual E, Rivera Díaz R, Ruiz-Villaverde R, Taberner Ferrer R, Vicente Villa A, Carrascosa JM. Management of Psoriasis During Preconception, Pregnancy, Postpartum, and Breastfeeding: A Consensus Statement. Actas Dermosifiliogr (Engl Ed) 2021;112:225-41. [PMID: 33065101 DOI: 10.1016/j.ad.2020.10.002] [Reference Citation Analysis]
35 Krause ML, Amin S, Makol A. Use of DMARDs and biologics during pregnancy and lactation in rheumatoid arthritis: what the rheumatologist needs to know. Ther Adv Musculoskelet Dis 2014;6:169-84. [PMID: 25342996 DOI: 10.1177/1759720X14551568] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
36 Maccari F, Fougerousse AC, Esteve E, Frumholtz L, Parier J, Hurabielle C, Cassius C, Taieb C; GEM RESOPSO and the AJDerm. Crossed looks on the dermatologist's position and the patient's preoccupations as to psoriasis and pregnancy: preliminary results of the PREGNAN-PSO study. J Eur Acad Dermatol Venereol 2019;33:880-5. [PMID: 30633377 DOI: 10.1111/jdv.15423] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
37 Mena-vazquez N. Safety of biologic therapies during pregnancy in women with rheumatic disease. WJR 2015;5:82. [DOI: 10.5499/wjr.v5.i2.82] [Cited by in CrossRef: 1] [Article Influence: 0.2] [Reference Citation Analysis]
38 Brown SM, Aljefri K, Waas R, Hampton P. Systemic medications used in treatment of common dermatological conditions: safety profile with respect to pregnancy, breast feeding and content in seminal fluid. J Dermatolog Treat 2019;30:2-18. [PMID: 28092212 DOI: 10.1080/09546634.2016.1202402] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
39 Förger F, Zbinden A, Villiger PM. Certolizumab treatment during late pregnancy in patients with rheumatic diseases: Low drug levels in cord blood but possible risk for maternal infections. A case series of 13 patients. Joint Bone Spine 2016;83:341-3. [DOI: 10.1016/j.jbspin.2015.07.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 26] [Article Influence: 6.4] [Reference Citation Analysis]
40 Ling J, Koren G. Challenges in vaccinating infants born to mothers taking immunoglobulin biologicals during pregnancy. Expert Review of Vaccines 2016;15:239-56. [DOI: 10.1586/14760584.2016.1115351] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 3.2] [Reference Citation Analysis]
41 Baronaite Hansen R, Kavanaugh A. Certolizumab pegol for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology 2015;11:307-18. [DOI: 10.1586/1744666x.2015.1009897] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
42 Silva JR, Ferreira LF, Oliveira PV, Nunes IV, Pereira ÍS, Timenetsky J, Marques LM, Figueiredo TB, Silva RA. Intra-uterine experimental infection by Ureaplasma diversum induces TNF-α mediated womb inflammation in mice. An Acad Bras Ciênc 2016;88:643-52. [DOI: 10.1590/0001-3765201620150244] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
43 Afzali A. Inflammatory bowel disease during pregnancy: management of a disease flare or remission. Current Opinion in Gastroenterology 2019;35:281-7. [DOI: 10.1097/mog.0000000000000541] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
44 van der Woude CJ, Metselaar HJ, Danese S. Management of gastrointestinal and liver diseases during pregnancy. Gut 2014;63:1014-23. [DOI: 10.1136/gutjnl-2013-305418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
45 Hassid B, Mahadevan U. The use of biologic therapy in pregnancy: a gastroenterologist's perspective. Curr Opin Rheumatol 2014;26:347-53. [PMID: 24625373 DOI: 10.1097/BOR.0000000000000048] [Cited by in Crossref: 17] [Cited by in F6Publishing: 1] [Article Influence: 2.4] [Reference Citation Analysis]
46 Huang VW, Chang HJ, Kroeker KI, Goodman KJ, Hegadoren KM, Dieleman LA, Fedorak RN. Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding Varies Widely: A Need for Further Education. Can J Gastroenterol Hepatol 2016;2016:6193275. [PMID: 27725926 DOI: 10.1155/2016/6193275] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
47 Lund T, Thomsen SF. Use of TNF-inhibitors and ustekinumab for psoriasis during pregnancy: A patient series. Dermatol Ther 2017;30. [PMID: 28071837 DOI: 10.1111/dth.12454] [Cited by in Crossref: 22] [Cited by in F6Publishing: 15] [Article Influence: 5.5] [Reference Citation Analysis]
48 Billiet T, Rutgeerts P, Ferrante M, Van Assche G, Vermeire S. Targeting TNF-α for the treatment of inflammatory bowel disease. Expert Opinion on Biological Therapy 2013;14:75-101. [DOI: 10.1517/14712598.2014.858695] [Cited by in Crossref: 85] [Cited by in F6Publishing: 86] [Article Influence: 10.6] [Reference Citation Analysis]
49 Ateka-Barrutia O, Nelson-Piercy C. Connective tissue disease in pregnancy. Clin Med (Lond) 2013;13:580-4. [PMID: 24298106 DOI: 10.7861/clinmedicine.13-6-580] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.4] [Reference Citation Analysis]
50 Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford). 2014;53:1377-1385. [PMID: 24352337 DOI: 10.1093/rheumatology/ket409] [Cited by in Crossref: 73] [Cited by in F6Publishing: 58] [Article Influence: 9.1] [Reference Citation Analysis]
51 Marder W, Littlejohn EA, Somers EC. Pregnancy and autoimmune connective tissue diseases. Best Pract Res Clin Rheumatol 2016;30:63-80. [PMID: 27421217 DOI: 10.1016/j.berh.2016.05.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 18] [Article Influence: 6.0] [Reference Citation Analysis]
52 Bröms G, Granath F, Ekbom A, Hellgren K, Pedersen L, Sørensen HT, Stephansson O, Kieler H. Low Risk of Birth Defects for Infants Whose Mothers Are Treated With Anti–Tumor Necrosis Factor Agents During Pregnancy. Clinical Gastroenterology and Hepatology 2016;14:234-241.e5. [DOI: 10.1016/j.cgh.2015.08.039] [Cited by in Crossref: 41] [Cited by in F6Publishing: 40] [Article Influence: 8.2] [Reference Citation Analysis]
53 Cao RH, Grimm MC. Pregnancy and medications in inflammatory bowel disease. Obstet Med 2021;14:4-11. [PMID: 33995565 DOI: 10.1177/1753495X20919214] [Reference Citation Analysis]
54 Saavedra MA, Romo-Rodríguez R, Gutiérrez-Ureña SR, Miranda-Hernández D, Hernández-Cruz LI, Jara LJ. Targeted drugs in spondyloarthritis during pregnancy and lactation. Pharmacol Res 2018;136:21-8. [PMID: 30125669 DOI: 10.1016/j.phrs.2018.08.009] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
55 Mosli MH, Al-Harbi O, Feagan BG, Almadi MA. A Saudi Gastroenterology association position statement on the use of tumor necrosis factor-alfa antagonists for the treatment of inflammatory bowel disease. Saudi J Gastroenterol. 2015;21:185-197. [PMID: 26228361 DOI: 10.4103/1319-3767.161635] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]